legal scope of the ‘moral exclusion’ clause in Article 6 of Directive 98/44EC of 6 July 1998 on the legal protection of biotechnological inventions, 1. Welcomes the setting up of an informal Group of Advisers on the Ethical Implications of Biotechnology, as announced in the first report under Article 16(c), which is mandated to analyse important issues surrounding biotechnological inventions and advise the Commission on the preparation of future reports; 2. Welcomes the Commission proposal to monitor any consequences of possible divergences between Member States’ legislation; 3. Welcomes the decision of the Commission to launch a further study looking at the ethical and legal aspects of stem cell patenting; Conclusions 4. Shares, with regard to the issue of whether patents on gene sequences (DNA sequences) should be allowed in accordance with the classical model of patent, the Commission’s conclusion of not taking a position now, but continuing to monitor developments and awaiting the outcome of the abovementioned study; 5. Supports the conclusions of the second report concerning the scope of patents and the patentability of stem cells; 6. Suggests that the European Parliament produce a report on the second report from the Commission; 7. Calls on the European Commission to continue monitoring developments, taking into account both the ethical aspects and the potential impact on competitiveness; 8. Instructs its President to forward this resolution to the Council, the Commission and the governments and parliaments of the EU Member States.